P3 Health Partners Inc. current report, 24 May 2021

Filing Overview

This Form 8-K was filed by Foresight Acquisition Corp., not P3 Health Partners Inc., on May 24, 2021. It reports an accounting correction related to the company’s warrants following SEC staff guidance issued April 12, 2021.

Business Context and Reporting Period

Foresight Acquisition Corp. was a special purpose acquisition company. The filing relates to the company’s audited balance sheet as of February 12, 2021, its IPO date, and the planned March 31, 2021 Form 10-Q.

Financial Metrics and Liquidity

  • The filing does not provide updated revenue, profit, cash flow, margin, debt, or liquidity figures.
  • The outstanding warrants were initially classified as equity but will be reclassified as liabilities at fair value.
  • Subsequent changes in warrant fair value will be recorded in earnings or loss in each reporting period.
  • Management stated that the reclassification is not expected to affect cash or cash held in the trust account.

Material Changes and Unusual Items

  • Management and the Audit Committee concluded that the previously filed audited balance sheet as of February 12, 2021 should no longer be relied upon.
  • The company’s independent auditor, Marcum LLP, also concluded that its audit report included in the February 19, 2021 Form 8-K should no longer be relied upon.
  • The company planned to reflect the warrant-liability reclassification in its upcoming Form 10-Q for the quarter ended March 31, 2021.

Outlook, Risks, and Contingencies

The primary issue is the accounting and valuation impact of classifying warrants as liabilities rather than equity. Although management does not expect a cash or trust-account impact, future changes in warrant fair value may create material non-cash volatility in reported results.

Important Facts to Verify

  • Confirm that the filing pertains to Foresight Acquisition Corp. rather than P3 Health Partners Inc.
  • Review the subsequent March 31, 2021 Form 10-Q for the corrected balance sheet and warrant valuation.
  • Assess the effect of fair-value warrant changes on reported net income or loss and shareholders’ equity.
  • Confirm any updated audit report or financial statements issued after the non-reliance notice.
  • Verify that cash balances and trust-account amounts remained unchanged.